C4 Therapeutics Inc (CCCC) — Capital Reinvestment Ratio

Latest as of June 2019: 0.02x

C4 Therapeutics Inc (CCCC) has a Capital Reinvestment Ratio of 0.02x as of June 2019, meaning it reinvests 0% of its operating cash flow ($36.91 Million) in capital expenditures ($641.00K). See net asset quality index of C4 Therapeutics Inc to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.02x
Capex / Operating Cash Flow

Operating Cash Flow

$36.91 Million
USD

Capital Expenditures

$641.00K
USD

Data as of

Jun 2019
Most recent filing

C4 Therapeutics Inc Capital Reinvestment Ratio (2019–2019)

This chart tracks C4 Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. Check total reinvestment intensity of C4 Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for C4 Therapeutics Inc (2019–2019)

Year-by-year Capital Reinvestment Ratio for C4 Therapeutics Inc from 2019 to 2019. For live market cap and broader valuation context, see C4 Therapeutics Inc (CCCC) total market value.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2019 0.02x $55.61 Million $1.35 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow